CL2016000008A1 - Tratamiento de lesiones inflamatorias de rosacea con ivermectina. - Google Patents

Tratamiento de lesiones inflamatorias de rosacea con ivermectina.

Info

Publication number
CL2016000008A1
CL2016000008A1 CL2016000008A CL2016000008A CL2016000008A1 CL 2016000008 A1 CL2016000008 A1 CL 2016000008A1 CL 2016000008 A CL2016000008 A CL 2016000008A CL 2016000008 A CL2016000008 A CL 2016000008A CL 2016000008 A1 CL2016000008 A1 CL 2016000008A1
Authority
CL
Chile
Prior art keywords
rosacea
treatment
ivermectin
inflammatory lesions
composition
Prior art date
Application number
CL2016000008A
Other languages
English (en)
Inventor
Jean Jacovella
Alexandre Kaoukhov
Michael Graeber
Laurence Salin
Michel Poncet
Philippe Briantais
Jean Paul Chappuis
Wagner Nathalie Sordello
Khaled Benkali
Original Assignee
Galderma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52133217&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2016000008(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Galderma Sa filed Critical Galderma Sa
Publication of CL2016000008A1 publication Critical patent/CL2016000008A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J9/00—Feeding-bottles in general
    • A61J9/06—Holders for bottles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/14—Ectoparasiticides, e.g. scabicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

USO DE UNA COMPOSICION QUE COMPRENDE 0,5 A 1,5% DE IVERMECTINA Y UN PORTADOR FARMACEUTICAMENTE ACEPTABLE, PARA EL TRATAMIENTO DE LESIONES INFLAMATORIAS DE LA ROSACEA, DONDE LA COMPOSICION SE ADMINISTRA POR VIA TOPICA.
CL2016000008A 2013-07-08 2016-01-05 Tratamiento de lesiones inflamatorias de rosacea con ivermectina. CL2016000008A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361843540P 2013-07-08 2013-07-08
US201361919208P 2013-12-20 2013-12-20
US201461927717P 2014-01-15 2014-01-15
US14/209,927 US9233117B2 (en) 2013-07-08 2014-03-13 Treatment of inflammatory lesions of rosacea with ivermectin

Publications (1)

Publication Number Publication Date
CL2016000008A1 true CL2016000008A1 (es) 2016-08-05

Family

ID=52133217

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2016000009A CL2016000009A1 (es) 2013-07-08 2016-01-05 Tratamiento de rosacea papulopustular con ivermectina.
CL2016000008A CL2016000008A1 (es) 2013-07-08 2016-01-05 Tratamiento de lesiones inflamatorias de rosacea con ivermectina.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CL2016000009A CL2016000009A1 (es) 2013-07-08 2016-01-05 Tratamiento de rosacea papulopustular con ivermectina.

Country Status (17)

Country Link
US (12) US9233117B2 (es)
EP (2) EP3019174A1 (es)
JP (8) JP2016526572A (es)
KR (2) KR101864799B1 (es)
CN (4) CN111467301A (es)
AU (2) AU2014287422B2 (es)
BR (2) BR112016000350A8 (es)
CA (2) CA2916668A1 (es)
CL (2) CL2016000009A1 (es)
HK (2) HK1223841A1 (es)
IL (3) IL243314B (es)
MX (2) MX2016000121A (es)
NZ (2) NZ716033A (es)
RU (2) RU2633076C2 (es)
SG (2) SG11201510420UA (es)
WO (2) WO2015006319A1 (es)
ZA (1) ZA201600358B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105916511A (zh) 2013-11-29 2016-08-31 盖尔德玛公司 用于治疗和/或预防特应性皮炎的阿维菌素家族或美贝霉素家族的化合物
US20170232024A1 (en) 2014-08-04 2017-08-17 Jerry Tan Eye Surgery Pte Ltd Pharmaceutical compositions for demodex related blepharitis and eyelid crusting
FR3032616B1 (fr) * 2015-02-12 2017-02-24 Galderma Sa Compose de la famille des avermectines pour le traitement et/ou la prevention des folliculites
EP3377063B1 (en) * 2015-11-17 2023-08-09 Galderma S.A. Use of ivermectin and brimonidine in the treatment and/or prevention of moderate to severe rosacea
RU2738932C2 (ru) * 2016-08-04 2020-12-18 Нестле Скин Хелт Са Композиции и их применение для лечения или профилактики розацеа
CN106397233A (zh) * 2016-08-26 2017-02-15 南通奥凯生物技术开发有限公司 一种医药级乙二胺四乙酸二钠的制备方法
US11160780B2 (en) * 2016-09-30 2021-11-02 Aurobindo Pharma Ltd. Pharmaceutical composition of ivermectin and process for preparation thereof
CN119157876A (zh) 2017-12-15 2024-12-20 塔苏斯制药有限公司 用于治疗睑炎的异恶唑啉驱虫剂制剂和方法
CN112638490B (zh) 2018-06-15 2023-01-03 格雷斯公司 消泡剂活性物质、其制造方法和消泡制剂
JP7129005B2 (ja) * 2018-09-28 2022-09-01 Toto株式会社 水洗大便器
DE202020005611U1 (de) 2019-02-18 2021-10-25 Mary Kay Inc. Topische Hautzusammensetzung zur Behandlung von Rosazea und Hautröte
US12502377B2 (en) 2019-04-04 2025-12-23 Tarsus Pharmaceuticals, Inc. Method of eradicating ticks that attach to humans using lotilaner formulations
CN111728959B (zh) * 2020-08-11 2023-02-03 黑龙江天龙药业有限公司 一种抑制油脂分泌且清螨虫的鼻膜贴及其制备方法
EP4062907A1 (fr) 2021-03-23 2022-09-28 Substipharm Formulation par voie orale d'ivermectine et utilisations
WO2022269665A1 (ja) * 2021-06-21 2022-12-29 マルホ株式会社 外用剤
KR102346125B1 (ko) 2021-10-15 2022-01-03 (주)나비바이오텍 이버멕틴 정성 검사용 래피드 키트
JP2024030763A (ja) * 2022-08-25 2024-03-07 学校法人神戸学院 皮膚炎症症状抑制用組成物

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ197796A (en) 1980-08-04 1984-11-09 Merck & Co Inc Stabilised aqueous formulations containing ivermectin
US5332577A (en) 1988-12-27 1994-07-26 Dermamed Transdermal administration to humans and animals
US5656280A (en) 1994-12-06 1997-08-12 Helene Curtis, Inc. Water-in-oil-in-water compositions
FR2754452B1 (fr) 1996-10-11 2003-02-14 Oreal Emulsion h/e a forte teneur en electrolytes et leur utilisation en dermo-cosmetique, notamment pour traiter les phenomenes d'irritation et/ou de peaux sensibles
US5952372A (en) 1998-09-17 1999-09-14 Mcdaniel; William Robert Method for treating rosacea using oral or topical ivermectin
FR2787322B1 (fr) 1998-12-18 2002-10-18 Galderma Res & Dev Emulsion huile-dans-eau comprenant un agent actif micronise et un systeme emulsionnant approprie
US6133310A (en) 1999-08-26 2000-10-17 Parks; L. Dean Method of treatment of rosacea
US6720001B2 (en) 1999-10-18 2004-04-13 Lipocine, Inc. Emulsion compositions for polyfunctional active ingredients
US6399652B1 (en) 2000-06-29 2002-06-04 L. Dean Parks Method of treating acne vulgaris using avermectin compound
US6319945B1 (en) 2000-06-29 2001-11-20 L. Dean Parks Method of treatment of seborrheic dermatitis
US6399651B1 (en) 2000-06-29 2002-06-04 L. Dean Parks Method of treating dermatoses using avermectin compound
DE10063946A1 (de) 2000-12-20 2002-07-04 Basf Ag Verwendung von Lichtschutzmittelkombinationen, die als wesentlichen Bestandteil 2,2'-p-Phenylen-bis(3,1-benzoxazin-4-on) enthalten als photostabile UV-Filter in kosmetischen und pharmazeutischen Zubereitungen
EP1476121A4 (en) 2002-02-08 2010-10-27 Merck Sharp & Dohme TOPICAL IVERMECTIN COMPOSITION
WO2003075656A2 (en) 2002-03-04 2003-09-18 Divergence, Inc. Nematicidal fatty acid and fatty acid ester related compounds
FR2854074B1 (fr) * 2003-04-24 2007-11-23 Galderma Res & Dev Utilisation de l'ivermectine pour le traitement de desordres dermatologiques
WO2004093886A1 (en) 2003-04-24 2004-11-04 Galderma S.A. Topical formulation of ivermectin for the treatment of dermatological conditions
EP1600158A1 (en) 2004-05-26 2005-11-30 Galderma Research & Development, S.N.C. Use of ondansetron for the treatment of inflammation, and pharmaceutical compositions thereof
DE602005020912D1 (de) 2004-03-18 2010-06-10 Galderma Sa Ivermectin enthaltende creme
FR2867684B1 (fr) * 2004-03-18 2006-05-05 Galderma Sa Gel creme contenant de l'ivermectine
FR2883181B1 (fr) 2005-03-17 2007-05-18 Galderma Sa Composition a base d'une avermectine et d'acide azelaique notamment pour le traitement de la rosacee
FR2886851B1 (fr) 2005-06-10 2007-10-05 Galderma Sa Composition a base d'une avermectine et de metronidazole notamment pour le traitement de la rosacee
FR2886852B1 (fr) 2005-06-10 2007-11-23 Galderma Sa Composition a base d'une avermectine et d'hydrocortisone notamment pour le traitement de la rosacee
FR2886850B1 (fr) 2005-06-10 2007-10-05 Galderma Sa Composition a base d'une avermectine et de peroxyde de benzoyle notamment pour le traitement de la rosacee
FR2894823B1 (fr) 2005-12-20 2008-02-29 Galderma Sa Composition de type emulsion inverse comprenant de l'ivermectine, et ses utilisations en cosmetique et en dermatologie
FR2900052B1 (fr) 2006-04-19 2011-02-18 Galderma Sa Composition comprenant au moins une phase aqueuse et au moins une phase grasse comprenant de l'ivermectine
FR2906468B1 (fr) 2006-09-28 2012-09-21 Galderma Sa Utilisation de composes de la famille des avermectines pour le traitement de desordres dermatologiques
FR2907013B1 (fr) 2006-10-12 2012-09-21 Galderma Sa Produits de soin cutane a double compartiment comprenant de l'ivermectine, et leurs utilisations
FR2907012B1 (fr) 2006-10-12 2012-09-21 Galderma Sa Composition dermatologique comprenant des nanocapsules d'avermectine, son procede de preparation et son utilisation
US20120004200A1 (en) 2008-12-23 2012-01-05 Galderma S.A. Topical pharmaceutical composition containing a water-sensitive active principle
JP2012516320A (ja) 2009-01-30 2012-07-19 イッスム リサーチ デベロプメント カンパニー オブ ザ ヘブライ ユニバーシティ オブ エルサレム リミテッド 爪および皮膚を処置するための組成物
FR2942138A1 (fr) * 2009-02-16 2010-08-20 Galderma Res & Dev Association de composes pour le traitement ou la prevention des affections dermatologiques
FR3000397A1 (fr) 2012-12-31 2014-07-04 Galderma Res & Dev Combinaison de laropiprant et d'ivermectine pour le traitement de la rosacee

Also Published As

Publication number Publication date
CN105792829A (zh) 2016-07-20
MX2016000121A (es) 2016-07-14
US20180207188A1 (en) 2018-07-26
RU2633481C2 (ru) 2017-10-12
JP2017197562A (ja) 2017-11-02
CN111467301A (zh) 2020-07-31
JP2023052490A (ja) 2023-04-11
US20150011489A1 (en) 2015-01-08
US20160175337A1 (en) 2016-06-23
SG11201510420UA (en) 2016-01-28
AU2014287408A1 (en) 2016-02-11
IL274058B (en) 2022-02-01
JP2016523968A (ja) 2016-08-12
KR101864799B1 (ko) 2018-06-05
CN105828825A (zh) 2016-08-03
IL243314B (en) 2022-02-01
JP2018184437A (ja) 2018-11-22
JP2016526572A (ja) 2016-09-05
MX2016000122A (es) 2016-06-15
US20180177813A1 (en) 2018-06-28
AU2014287422A1 (en) 2016-02-11
CA2916704A1 (en) 2015-01-15
BR112016000335A8 (pt) 2020-01-07
NZ716033A (en) 2017-01-27
HK1223842A1 (zh) 2017-08-11
KR20160061311A (ko) 2016-05-31
CA2916704C (en) 2018-11-20
AU2014287408B2 (en) 2017-05-04
RU2633076C2 (ru) 2017-10-11
CN111494399A (zh) 2020-08-07
ZA201600358B (en) 2019-11-27
CA2916668A1 (en) 2015-01-15
AU2014287422B2 (en) 2017-04-13
CL2016000009A1 (es) 2016-08-19
US20210177882A1 (en) 2021-06-17
NZ716034A (en) 2017-01-27
IL243314A0 (en) 2016-02-29
US20150011490A1 (en) 2015-01-08
US20220347198A1 (en) 2022-11-03
JP2021059590A (ja) 2021-04-15
US20160184342A1 (en) 2016-06-30
KR101863085B1 (ko) 2018-06-01
IL243315B (en) 2022-02-01
WO2015006319A1 (en) 2015-01-15
US9233117B2 (en) 2016-01-12
EP3019173A1 (en) 2016-05-18
BR112016000335A2 (pt) 2017-07-25
US10206939B2 (en) 2019-02-19
BR112016000350A8 (pt) 2020-01-07
US9233118B2 (en) 2016-01-12
JP6438466B2 (ja) 2018-12-12
WO2015006305A1 (en) 2015-01-15
US20150011491A1 (en) 2015-01-08
RU2016103753A (ru) 2017-08-11
US20160143935A1 (en) 2016-05-26
IL274058A (en) 2020-06-30
EP3019174A1 (en) 2016-05-18
US20200000835A1 (en) 2020-01-02
RU2016103715A (ru) 2017-08-11
HK1223841A1 (zh) 2017-08-11
SG11201510635PA (en) 2016-01-28
JP6653734B2 (ja) 2020-02-26
BR112016000350A2 (pt) 2017-07-25
US9089587B2 (en) 2015-07-28
IL243315A0 (en) 2016-02-29
JP2025143422A (ja) 2025-10-01
KR20160061310A (ko) 2016-05-31
US20180264021A1 (en) 2018-09-20
JP2019073527A (ja) 2019-05-16

Similar Documents

Publication Publication Date Title
ECSP19021223A (es) Derivado de glucagon, conjugado del mismo, composición que comprende el mismo y uso terapéutico del mismo
MX391858B (es) Compuestos terapeuticamente activos y sus metodos de uso
CL2015002164A1 (es) Formulación combinada de dos compuesos antivirales.
SV2015005115A (es) Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades
CL2018000222A1 (es) Nueva combinación para el uso en el tratamiento del cáncer
CL2015003117A1 (es) Modificaciones en la estructura cristalina
UY35040A (es) Pirrolopirimidinilamino-benzotiazolonas sustituidas
CL2016000783A1 (es) “compuestos derivados de isoquinolinona y quinazolinona, inhibidores pi3k; composición farmacéutica que los comprende; útiles en el tratamiento del cáncer, enfermedades inflamatorias y autoinmune”. pct
GT201400111A (es) Triazolopiridinas sustituidas
CL2016000009A1 (es) Tratamiento de rosacea papulopustular con ivermectina.
CR20150455A (es) Imidazopiridazinas sustituidas
NI201600006A (es) Pirazolo-piridinaminas sustituidas
CL2015002466A1 (es) Formulaciones de compuestos orgánicos
CO2017005968A2 (es) Pirazolpiridinaminas como inhibidores de mknk1 y mknk2
DOP2016000118A (es) Tienopirimidinas como inhibidores mknk1 y mknk2
ECSP14023048A (es) Agentes terapéuticos para administración subcutánea optimizados
CR20150653A (es) Compuestos nuevos para el tratamiento del cáncer
CL2016002879A1 (es) Composiciones farmacéuticas para tratar enfermedades infecciosas
ECSP13012988A (es) Derivados de tienopirimidina (2,3-d) y su uso para tratar arritmia
CL2016000397A1 (es) Tratamiento contra el cáncer
CO6480929A2 (es) Procedimiento de uso del factor liberador de corticotropina para el tratamiento del cancer
CL2016000542A1 (es) Composición que comprende hidroxipropil quitosano junto con excipientes y/o adyuvantes farmacéuticamente aceptables; útil en el tratamiento de la onicomicosis.
PE20150022A1 (es) Dronedarona para uso en la leishmaniosis, formulaciones y asociaciones para uso en la leishmaniosis
MX2017014998A (es) Uso de hidroxido de potasio en el tratamiento de la queratosis actinica.
TR201910467T4 (tr) Selektif PYY bileşikleri ve bunların kullanımları.